Matches in Wikidata for { <http://www.wikidata.org/entity/Q64801624> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- Q64801624 description "clinical trial" @default.
- Q64801624 description "ensayu clínicu" @default.
- Q64801624 description "klinisch onderzoek" @default.
- Q64801624 description "клінічне випробування" @default.
- Q64801624 description "կլինիկական փորձարկում" @default.
- Q64801624 name "Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer." @default.
- Q64801624 type Item @default.
- Q64801624 label "Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer." @default.
- Q64801624 prefLabel "Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer." @default.
- Q64801624 P1132 Q64801624-1199E72B-2AF9-4A05-8AEC-874114693063 @default.
- Q64801624 P1476 Q64801624-556F9723-4E99-4197-915C-D72A68C29379 @default.
- Q64801624 P17 Q64801624-521D8C41-B0DE-4599-8202-055C80EEB2C6 @default.
- Q64801624 P1813 Q64801624-A0AE9569-90B0-417E-B4DE-9BF4241685F3 @default.
- Q64801624 P2899 Q64801624-071B762E-D18D-49AD-A527-28D1D00ED12E @default.
- Q64801624 P3098 Q64801624-B4A5ABBB-20A2-4695-9DEB-2FE6A4D93DBC @default.
- Q64801624 P31 Q64801624-7461CE31-0535-47C7-9F1C-CA7F4B7E6A0F @default.
- Q64801624 P4844 Q64801624-92231330-24EE-4B45-A92F-30FAA93195A4 @default.
- Q64801624 P4844 Q64801624-AD331CE6-2500-45B9-AF5B-9C1B423E07BC @default.
- Q64801624 P4844 Q64801624-F4A8927B-8CCF-42EF-A698-EDEBD5EA2D22 @default.
- Q64801624 P4844 Q64801624-F6B4E6DF-81B2-41BD-81C1-89410F65570D @default.
- Q64801624 P580 Q64801624-142235F1-F203-430B-BF77-67DE31A9A3E9 @default.
- Q64801624 P582 Q64801624-FA9DAFDA-3BDA-4E51-9CA1-35DE3FC8BFE9 @default.
- Q64801624 P6099 Q64801624-263C3FB9-2EC7-41A0-B914-AE9367709C77 @default.
- Q64801624 P6099 Q64801624-F92E4F8A-3111-4CB9-9C43-2CA4046820DC @default.
- Q64801624 P767 Q64801624-491A893C-D475-4799-8304-458415A58C03 @default.
- Q64801624 P8363 Q64801624-BE4D4861-74D7-46B7-850D-949C5ADC268A @default.
- Q64801624 P1132 "+234" @default.
- Q64801624 P1476 "A Randomized Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer Preceded by a Phase I Dose Escalation Study on Rucaparib-Bevacizumab Combination." @default.
- Q64801624 P17 Q38 @default.
- Q64801624 P1813 "MITO25" @default.
- Q64801624 P2899 "+18" @default.
- Q64801624 P3098 "NCT03462212" @default.
- Q64801624 P31 Q30612 @default.
- Q64801624 P4844 Q413299 @default.
- Q64801624 P4844 Q415588 @default.
- Q64801624 P4844 Q423762 @default.
- Q64801624 P4844 Q7376558 @default.
- Q64801624 P580 "2018-02-20T00:00:00Z" @default.
- Q64801624 P582 "2018-11-01T00:00:00Z" @default.
- Q64801624 P6099 Q42824440 @default.
- Q64801624 P6099 Q5452194 @default.
- Q64801624 P767 Q19604401 @default.
- Q64801624 P8363 Q78089383 @default.